{"id":54893,"title":"Oxford Nanopore Shares Slide as First-Half Revenue Misses Expectations","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-07-13T16:33:06+00:00","modified":"2026-07-13T16:33:06+00:00","canonical_url":"https://stockmark.it/oxford-nanopore-shares-slide-as-first-half-revenue-misses-expectations/","markdown_url":"https://stockmark.it/oxford-nanopore-shares-slide-as-first-half-revenue-misses-expectations.md","json_url":"https://stockmark.it/oxford-nanopore-shares-slide-as-first-half-revenue-misses-expectations.json","category":"Biotech","categories":["Biotech"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-news-2.jpg?fit=1200%2C500&quality=89&ssl=1","excerpt":"Oxford Nanopore expects first-half revenue of about £116.5 million after weaker trading in China and the Middle East and slower order timing in the Americas.","format":"news","language":"en-GB","content":"Oxford Nanopore Technologies has warned that first-half revenue was below management expectations after weaker trading in China, disruption in the Middle East and slower-than-expected order timing in the Americas.\n\nThe FTSE 250-listed DNA and RNA sequencing specialist expects first-half 2026 revenue of approximately £116.5 million, representing 12% year-on-year growth at constant currency. China revenue declined 16%, while Middle East revenue fell 14% amid regional disruption.\n\n## Why it matters\n\nThe update raises execution risk around Oxford Nanopore’s near-term growth trajectory and highlights its exposure to export controls, geopolitical disruption and uneven customer-order timing. Management nevertheless said it expects a materially stronger second half and remains on track to reach adjusted EBITDA breakeven during 2027.\n\n**Company:** Oxford Nanopore Technologies plc\n\n**Ticker:** LSE: ONT\n\n**Sector:** Pharmaceuticals / Biotechnology\n\n**UK release time:** 13 July 2026, approximately 07:00 BST\n\n**Sources:** Oxford Nanopore Technologies trading update; London Stock Exchange/RNS; Reuters market reporting."}